Abstract
BACKGROUND: A novel generation of rabbit monoclonal antibodies has been released recently for estrogen (ER) and progesterone (PR) receptor evaluation in breast cancer by immunohistochemistry. Aims: We compared novel rabbit monoclonal antibodies anti-ER SP1 (LabVision®) and B644 (Cell Marque®) to mouse monoclonal antibodies 1D5 (Dako®) and 6F11 (Novocastra®) using a tissue microarray of breast carcinomas. METHODS: Two cylinders (2 mm diameter) of formalin-fixed paraffin embedded tissue were obtained from 24 invasive breast carcinomas and immunostained by using the anti-ER rabbit and mouse antibodies and the streptavidin-biotin detection system (Biogenex®). Immunostaining was evaluated considering positive those tumors in which more than 10% of the tumor cell nuclei stained. The stain intensity was also evaluated as weak (1), moderate (2), and strong (3). Results: Both rabbit antibodies against ER have similar staining pattern to each other and also to 6F11, but significantly stronger scores compared to mouse 1D5. The rabbit antibodies allow better cost/benefit because of higher working dilutions compared to mouse antibodies using the same procedure. CONCLUSION: The new rabbit antibodies against ER are highly sensitive and reliable in clinical and research immunohistochemical testing of breast carcinomas.
Highlights
Estrogen receptor (ER) may be the best example of a tumor biomarker with an assay that drives therapeutic decision-making[7, 17]
Since 1990, pathology has played an important role in diagnosis, and by providing additional information about prognostic and predictive molecular markers aimed at the best breast cancer treatment[22]
Since the release of monoclonal and polyclonal antibodies that react in formalin-fixed paraffinembedded tissue, scientists have been evaluating ER almost exclusively by immunohistochemistry[1, 5, 8, 19, 25]
Summary
Estrogen receptor (ER) may be the best example of a tumor biomarker with an assay that drives therapeutic decision-making[7, 17]. Since the release of monoclonal and polyclonal antibodies that react in formalin-fixed paraffinembedded tissue, scientists have been evaluating ER almost exclusively by immunohistochemistry[1, 5, 8, 19, 25]. Several different methods and different antibodies against ER have been used for immunohistochemistry testing. As with any laboratory method, technical details have a great effect on the final result[11, 20, 21]. A novel generation of rabbit monoclonal antibodies has been released recently for estrogen (ER) and progesterone (PR) receptor evaluation in breast cancer by immunohistochemistry. Aims: We compared novel rabbit monoclonal antibodies anti-ER SP1 (LabVision®) and B644 (Cell Marque®) to mouse monoclonal antibodies 1D5 (Dako®) and 6F11 (Novocastra®) using a tissue microarray of breast carcinomas
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call